Plasma Fractionation Market Introduction and Overview
According to SPER Market Research, the Global Plasma Fractionation Market is estimated to reach USD 82.93 billion by 2034 with a CAGR of 8.73%.
The report includes an in-depth analysis of the Global Plasma Fractionation Market, including market size and trends, product mix, Applications, and supplier analysis. The global plasma fractionation market was valued at USD 35.91 billion in 2024 and is expected to increase at an 8.73% CAGR from 2025 to 2034. The key driver of market growth is the growing worldwide population of senior people, who are more susceptible to unusual illnesses needing blood derivatives. Furthermore, the increasing use of immunoglobulins and alpha-1-antitrypsin in numerous medical domains around the world is likely to drive market growth. The global expansion of blood collection facilities has also contributed significantly to this surge.
By Product Insights: The immunoglobulins segment led the market in revenue share in 2024 due to its common use in treating immune deficiencies, autoimmune diseases, and neurological disorders. The rise in these conditions, especially in older populations, has increased the demand for immunoglobulin therapies. Improvements in plasma collection and safety, along with greater awareness and access to these treatments, are driving this segment's growth.
By Method Insights: The chromatography segment dominated the market in 2024. The use of industrial-scale chromatographic fractionation and purification procedures for plasma fractionation has lately grown. A new generation of therapeutic plasma products, including coagulation factors, protease inhibitors, and anticoagulants, has been created. As a result, chromatography has enabled the development of new therapeutics for treating individuals with acquired or congenital abnormalities in plasma protein levels. As a result, it will accelerate market expansion.
By Application Insights: The neurology segment had the largest revenue share in 2024 because of the growing acceptance of plasma-derived therapies for neurological disorders. Conditions such as multiple sclerosis, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy are now being treated with therapies like intravenous immunoglobulin (IVIg) and plasmapheresis. Increasing cases of these disorders, along with advancements in research and new treatment methods, are driving the demand for plasma-derived products. Awareness among healthcare professionals about the effectiveness of these therapies is also boosting growth in this segment.
By End User Insights: Hospitals and clinics held the largest revenue share in 2024 and are expected to grow the fastest in the coming years. This growth is fueled by the rising demand for plasma-derived therapies in various medical uses. They provide important treatments like intravenous immunoglobulin (IVIg) and albumin for immune disorders, liver diseases, and trauma. The increase in chronic illnesses and an aging population has led to more patient admissions, boosting the need for plasma treatments. Advances in plasma collection and storage are also improving access to these treatments.
By Regional Insights: North America dominated the global plasma fractionation market in 2024, capturing a large share due to greater awareness and benefits of plasma among its citizens, along with a rise in respiratory disorders. Key factors include significant players, more plasma collection facilities, increased immunoglobulin consumption, and efficient plasma supply and distribution.
Market Competitive Landscape:
Key market participants are launching a variety of initiatives to improve their market presence and reach for their products and services. Expansion activities and collaborations are significant strategies for driving industry growth. Key market players are Grifols S.A, CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A, Biotest AG, and others.
Recent Developments:
- Takeda announced in January 2024 that the FDA had authorized Immune Globulin Infusion 10% solution as an intravenous immunoglobulin therapy for treating neuromuscular dysfunction and impairment in adults with chronic inflammatory demyelinating polyneuropathy.
- In July 2024, Biotest AG stated that it had laid the framework for an agreement with Kedrion to fully commercialize and distribute its immunoglobulin product, Yimmugo, in the United States. The FDA previously approved Yimmugo's Biologic License Application (BLA).
- The Food and Drug Administration (FDA) approved CSL's (Australia) 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) in April 2023 for use in patients with PI and CIPD.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Method, By Application, By End-User. |
| Regions covere | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Grifols S.A, CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A, Biotest AG, Sanquin, Bio Products Laboratory Ltd, Intas Pharmaceuticals Ltd. |
Key Topics Covered in the Report:
- Global Plasma Fractionation Market Size (FY’2021-FY’2034)
- Overview of Global Plasma Fractionation Market
- Segmentation of Global Plasma Fractionation Market By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease inhibitors, Others)
- Segmentation of Global Plasma Fractionation Market By Method (Centrifugation, Depth Filtration, Chromatography, Others)
- Segmentation of Global Plasma Fractionation Market By Application (Neurology, Hematology, Oncology, Immunology, Pulmonology, Others)
- Segmentation of Global Plasma Fractionation Market By End User (Hospitals & Clinics, Clinical Research, Others)
- Statistical Snap of Global Plasma Fractionation Market
- Expansion Analysis of Global Plasma Fractionation Market
- Problems and Obstacles in Global Plasma Fractionation Market
- Competitive Landscape in the Global Plasma Fractionation Market
- Details on Current Investment in Global Plasma Fractionation Market
- Competitive Analysis of Global Plasma Fractionation Market
- Prominent Players in the Global Plasma Fractionation Market
- SWOT Analysis of Global Plasma Fractionation Market
- Globa Plasma Fractionation Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Plasma Fractionation Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Plasma Fractionation Market
7. Global Plasma Fractionation Market, By Product (USD Million) 2021-2034
7.1. Albumin
7.2. Immunoglobulins
7.2.1. Intravenous immunoglobulins
7.2.2. Subcutaneous immunoglobulins
7.2.3. Other immunoglobulins
7.3. Coagulation Factors
7.3.1. Factor VIII
7.3.2. Factor IX
7.3.3. VON WILLEBRAND factor
7.3.4. Prothrombin complex concentrates
7.3.5. Fibrinogen concentrates
7.3.6. Others
7.4. Protease inhibitors
7.5. Others
8. Global Plasma Fractionation Market, By Method (USD Million) 2021-2034
8.1. Centrifugation
8.2. Depth Filtration
8.3. Chromatography
8.4. Others
9. Global Plasma Fractionation Market, By Application (USD Million) 2021-2034
9.1. Neurology
9.2. Hematology
9.3. Oncology
9.4. Immunology
9.5. Pulmonology
9.6. Others
10. Global Plasma Fractionation Market, By End User (USD Million) 2021-2034
10.1. Hospitals & Clinics
10.2. Clinical Research
10.3. Others
11. Global Plasma Fractionation Market, (USD Million) 2021-2034
11.1. Global Plasma Fractionation Market Size and Market Share
12. Global Plasma Fractionation Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Grifols S.A
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. CSL Limited
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Takeda Pharmaceutical Company Limited
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Octapharma AG
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Kedrion S.p.A
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. LFB S.A
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Biotest AG
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Sanquin
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Bio Products Laboratory Ltd
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Intas Pharmaceuticals Ltd
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
